3B Blackbio Dx Limited (BOM:532067)

Market Cap	10.96B -26.4%
Revenue (ttm)	1.29B +32.8%
Net Income	574.68M +21.0%
EPS	67.66 +19.0%
Shares Out	8.57M
PE Ratio	18.90
Forward PE	n/a
Dividend	4.00 (0.32%)
Ex-Dividend Date	Sep 19, 2025

Volume	2,242
Average Volume	9,659
Open	1,250.15
Previous Close	1,252.10
Day's Range	1,228.75 - 1,296.00
52-Week Range	1,110.00 - 2,019.90
Beta	0.40
RSI	50.20
Earnings Date	May 26, 2026

About 3B Blackbio Dx

3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and t...

• Industry: Agricultural Chemicals
• Founded: 1972
• Employees: 85
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532067

Financial Performance

In fiscal year 2025, 3B Blackbio Dx's revenue was 964.69 million, an increase of 29.64% compared to the previous year's 744.13 million. Earnings were 476.91 million, an increase of 48.56%.